Jim J Hagan

List of Publications by Year
in descending order

46 papers	4,238 citations	100601 38 h-index	252626 46 g-index
46 all docs	46 docs citations	46 times ranked	3600 citing authors

#	Article	IF	Citations
1	Enhanced appetitive learning and reversal learning in a mouse model for Prader-Willi syndrome.. Behavioral Neuroscience, 2012, 126, 488-492.	0.6	8
2	Behavioural and cognitive abnormalities in an imprinting centre deletion mouse model for Praderâ€“Willi syndrome. European Journal of Neuroscience, 2010, 31, 156-164.	1.2	58
3	N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor. Neuropharmacology, 2010, 58, 1206-1214.	2.0	24
4	Altered M1 Muscarinic Acetylcholine Receptor (CHRM1)-GÎ±q/11 Coupling in a Schizophrenia Endophenotype. Neuropsychopharmacology, 2009, 34, 2156-2166.	2.8	44
5	Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse, 2009, 63, 359-364.	0.6	49
6	Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats. European Neuropsychopharmacology, 2009, 19, 778-790.	0.3	25
7	The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology, 2008, 54, 1166-1174.	2.0	53
8	Pharmacological Assessment of M₁Muscarinic Acetylcholine Receptor-G_{q/11}Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 869-874.	1.3	24
9	SB-649915-B, a Novel 5-HT1A/B Autoreceptor Antagonist and Serotonin Reuptake Inhibitor, is Anxiolytic and Displays Fast Onset Activity in the Rat High Light Social Interaction Test. Neuropsychopharmacology, 2007, 32, 2163-2172.	2.8	44
10	1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines:â€‰ A Series of Potent and Selective Dopamine D₃ Receptor Antagonists. Journal of Medicinal Chemistry, 2007, 50, 5076-5089.	2.9	84
11	Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacology, 2007, 192, 121-133.	1.5	28
12	SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4â€²-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide) Tj ETQq0 0 0 rgb Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain. Neuropharmacology, 2006, 51, 566-577.	2.0	45
13	5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology, 2005, 181, 253-259.	1.5	111
14	Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia. Schizophrenia Bulletin, 2005, 31, 830-853.	2.3	105
15	Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Current Opinion in Pharmacology, 2005, 5, 107-118.	1.7	55
16	The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Research Reviews, 2005, 49, 77-105.	9.1	296
17	5-HT7 Receptors. CNS and Neurological Disorders, 2004, 3, 81-90.	4.3	150
18	The 5-HT6 Receptor Antagonist SB-271046 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats. Neuropsychopharmacology, 2004, 29, 93-100.	2.8	125

#	Article	IF	Citations
19	Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain. European Journal of Pharmacology, 2004, 493, 95-98.	1.7	7
20	Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology, 2004, 176, 57-65.	1.5	151
21	Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats. Psychopharmacology, 2004, 177, 1-14.	1.5	54
22	5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse, 2004, 51, 158-164.	0.6	143
23	Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse, 2003, 48, 154-156.	0.6	96
24	SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. British Journal of Pharmacology, 2003, 139, 705-714.	2.7	111
25	Design and Synthesis oftrans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 512 Td (phenyl) (SB-414796):Â A Potent and Selective Dopamine D3Receptor Antagonist. Journal of Medicinal Chemistry, 2003, 46, 4952-4964.	2.9	73
26	Attenuation of Cue-Controlled Cocaine-Seeking by a Selective D3 Dopamine Receptor Antagonist SB-277011-A. Neuropsychopharmacology, 2003, 28, 329-338.	2.8	167
27	Selective Antagonism at Dopamine D3 Receptors Prevents Nicotine-Triggered Relapse to Nicotine-Seeking Behavior. Neuropsychopharmacology, 2003, 28, 1272-1280.	2.8	138
28	Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex. Neuropsychopharmacology, 2003, 28, 839-849.	2.8	88
29	5-HT7 receptors modulate synchronized network activity in rat hippocampus. Neuropharmacology, 2002, 42, 82-92.	2.0	59
30	Dopamine D₃Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats. Journal of Neuroscience, 2002, 22, 9595-9603.	1.7	262
31	Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity. Psychopharmacology, 2001, 153, 210-218.	1.5	95
32	Central effects of urotensin-II following ICV administration in rats. Psychopharmacology, 2001, 155, 426-433.	1.5	70
33	Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. Psychopharmacology, 2001, 156, 338-351.	1.5	75
34	The effect of SB-269970, a 5-HT7 receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. British Journal of Pharmacology, 2001, 132, 1574-1580.	2.7	37
35	[3 H]-SB-269970 - A selective antagonist radioligand for 5-HT7 receptors. British Journal of Pharmacology, 2000, 130, 409-417.	2.7	68
36	Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. British Journal of Pharmacology, 2000, 130, 539-548.	2.7	257

#	Article	IF	Citations
37	A Novel, Potent, and Selective 5-HT7Antagonist:Â (R)-3-(2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970). Journal of Medicinal Chemistry, 2000, 43, 342-345.	2.9	235
38	Design and Synthesis oftrans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 712 Td (yl)ethyl]c Antagonist with High Oral Bioavailability and CNS Penetration in the Rat. Journal of Medicinal Chemistry, 2000, 43, 1878-1885.	2.9	128
39	Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long) , D3 and D4.4 receptors expressed in Chinese hamster ovary cells. British Journal of Pharmacology, 1999, 127, 1696-1702.	2.7	70
40	Influence of peptide CRF receptor antagonists upon the behavioural effects of human/rat CRF. European Journal of Pharmacology, 1999, 373, 141-145.	1.7	12
41	The behavioural effects of corticotropin-releasing factor-related peptides in rats. Psychopharmacology, 1998, 138, 124-132.	1.5	110
42	(R)-3,N-Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide:Â The First Selective 5-HT7Receptor Antagonist. Journal of Medicinal Chemistry, 1998, 41, 655-657.	2.9	102
43	The Selective 5-HT1B Receptor Inverse Agonist 1â€˜-Methyl-5-[[2â€˜-methyl-4â€˜-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro-spiro[furo[2,3-f]indole-3,4â€˜-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo. Journal of Medicinal Chemistry, 1998, 41, 1218-1235.	2.9	79
44	Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. European Journal of Pharmacology, 1997, 331, 169-174.	1.7	84
45	Parkinson's disease: prospects for improved drug therapy. Trends in Pharmacological Sciences, 1997, 18, 156-163.	4.0	63
46	Parkinson's disease: prospects for improved drug therapy. Trends in Pharmacological Sciences, 1997, 18, 156-163.	4.0	76